Remote symptom monitoring integrated into electronic health records: A systematic review

Abstract

Objective People with long-term conditions require serial clinical assessments. Digital patient-reported symptoms collected between visits can inform these, especially if integrated into electronic health records (EHRs) and clinical workflows. This systematic review identified and summarized EHR-integrated systems to remotely collect patient-reported symptoms and examined their anticipated and realized benefits in long-term conditions. Materials and Methods We searched Medline, Web of Science, and Embase. Inclusion criteria were symptom reporting systems in adults with long-term conditions; data integrated into the EHR; data collection outside of clinic; data used in clinical care. We synthesized data thematically. Benefits were assessed against a list of outcome indicators. We critically appraised studies using the Mixed Methods Appraisal Tool. Results We included 12 studies representing 10 systems. Seven were in oncology. Systems were technically and functionally heterogeneous, with the majority being fully integrated (data viewable in the EHR). Half of the systems enabled regular symptom tracking between visits. We identified 3 symptom report-guided clinical workflows: Consultation-only (data used during consultation, n = 5), alert-based (real-time alerts for providers, n = 4) and patient-initiated visits (n = 1). Few author-described anticipated benefits, primarily to improve communication and resultant health outcomes, were realized based on the study results, and were only supported by evidence from early-stage qualitative studies. Studies were primarily feasibility and pilot studies of acceptable quality. Discussion and Conclusions EHR-integrated remote symptom monitoring is possible, but there are few published efforts to inform development of these systems. Currently there is limited evidence that this improves care and outcomes, warranting future robust, quantitative studies of efficacy and effectiveness.

The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience

“…In our study access to (and knowledge of) technology did not emerge as barrier to the use of telemedicine. In this regard, the use of smartphone applications may improve the experience with telemedicine of pSS patients on one hand and ensure continuous monitoring of the disease on the other (15). Nevertheless, stakeholders developing such programs should carefully explore and take into account potential technical barriers that may affect implementation or acceptability by patients as recently emerged by a worldwide survey across rheumatologists (16).…”

The PICASO cloud platform for improved holistic care in rheumatoid arthritis treatment—experiences of patients and clinicians

“…All PICASO services were implemented in conformance with the established HL7/FHIR standard in order to enable modern data exchange with other software systems, a highly needed prerequisite for IT developments in the health care sector [ 40 ]. This standard ensured that data from other systems can be orchestrated in the platform and displayed in PDs and CDs.…”

“…Overall, the benefits of digital health applications are increasingly adopted to support health care, as they offer opportunities to improve knowledge and create new, optimized management processes [ 42 , 43 ]. They still have to prove a positive impact on care and outcomes, especially in long-term use [ 40 ]. Continuous use of such platforms like PICASO, with regular documentation of comprehensive rheumatologic and cardiovascular measurements, will result in a big data scenario.…”

Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors

“…However, the 74% median patient-level adherence rate of symptom reporting at least 3 times per week and the 73% care team automated alert review rate are within the expected range of what has previously been observed with electronic PRO symptom reporting in oncology. 10 , 12 , 18 , 19 , 20 , 21 For example, a feasibility trial found that participants with early-stage breast cancer who were receiving aromatase inhibitor therapy noted a weekly adherence rate of 38% with use of a web-based application, which increased to 74% with the addition of a weekly reminder. 19 Our study enrollment overlapped with the COVID-19 pandemic, which can confound comparisons with historical adherence expectations but also suggests that the platform demonstrated reasonable adherence rates by both patients and care teams despite the operational challenges imposed by the pandemic.…”